{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:18Z","timestamp":1793159838298,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04655-y","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:17:29Z","timestamp":1777879049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term effect of tirzepatide on serum calcitonin in adults with obesity"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8901-7161","authenticated-orcid":false,"given":"Nikolaos","family":"Angelopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Simeakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rizoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Boniakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Mentzelopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areti","family":"Korakovouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Zianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarantis","family":"Livadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodis","family":"Paparodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"4655_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/nejmoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"A.M. Jastreboff, L.J. Aronne, N.N. Ahmad et al., Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 387, 205\u2013217 (2022). https:\/\/doi.org\/10.1056\/nejmoa2206038","journal-title":"N. Engl. J. Med."},{"key":"4655_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/nejmoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"J.P. Fr\u00edas, M.J. Davies, J. Rosenstock et al., Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021). https:\/\/doi.org\/10.1056\/nejmoa2107519","journal-title":"N. Engl. J. Med."},{"key":"4655_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"J. Rosenstock, C. Wysham, J.P. Fr\u00edas et al., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 398, 143\u2013155 (2021). https:\/\/doi.org\/10.1016\/s0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"4655_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"B. Ludvik, F. Giorgino, E. J\u00f3dar et al., Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London England). 398, 583\u2013598 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet (London England)"},{"key":"4655_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"LW KnudsenLB, Madsen","year":"2010","unstructured":"L.W. KnudsenLB, Madsen, S. Andersen et al., Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. Endocrinology. 151, 1473\u20131486 (2010). https:\/\/doi.org\/10.1210\/en.2009-1272","journal-title":"Endocrinology"},{"key":"4655_CR6","unstructured":"EMA. Mounjaro - European Medicines Agency, European Medicines Agency. pages: 40-47. Published July 18, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro"},{"issue":"5922","key":"4655_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"M.G. Rosenfeld, J.J. Mermod, S.G. Amara et al., Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 304(5922), 129\u2013135 (1983). https:\/\/doi.org\/10.1038\/304129a0","journal-title":"Nature"},{"issue":"6","key":"4655_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"S.A. Wells, S.L. Asa, H. Dralle et al., Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 25(6), 567\u2013610 (2015). https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"issue":"2","key":"4655_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1476-5381.2009.00433.x","volume":"159","author":"KL Becker","year":"2009","unstructured":"K.L. Becker, R. Snider, E.S. Nylen, Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br. J. Pharmacol. 159(2), 253\u2013264 (2009). https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00433.x","journal-title":"Br. J. Pharmacol."},{"key":"4655_CR10","doi-asserted-by":"publisher","unstructured":"S.J. Kim, H.J. Yun, S. Shin, Y.S. Lee, H.S. Chang, Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center. Front. Endocrinol. 12 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.747704","DOI":"10.3389\/fendo.2021.747704"},{"issue":"2","key":"4655_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"A.S. Wattiez, L.P. Sowers, A.F. Russo, Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin. Ther. Targets. 24(2), 91\u2013100 (2020). https:\/\/doi.org\/10.1080\/14728222.2020.1724285","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"4655_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2337\/diab.39.2.260","volume":"39","author":"JM Molina","year":"1990","unstructured":"J.M. Molina, G.J.S. Cooper, B. Leighton, J.M. Olefsky, Induction of Insulin Resistance In Vivo by Amylin and Calcitonin Gene-Related Peptide. Diabetes. 39(2), 260\u2013265 (1990). https:\/\/doi.org\/10.2337\/diab.39.2.260","journal-title":"Diabetes"},{"issue":"9","key":"4655_CR13","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1210\/jc.2010-0305","volume":"95","author":"A Abbasi","year":"2010","unstructured":"A. Abbasi, E. Corpeleijn, D. Postmus et al., Plasma Procalcitonin Is Associated with Obesity, Insulin Resistance, and the Metabolic Syndrome. J. Clin. Endocrinol. Metabolism. 95(9), E26\u2013E31 (2010). https:\/\/doi.org\/10.1210\/jc.2010-0305","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"4655_CR14","unstructured":"U.S. Food, D. Administration, FDA. Victoza (Liraglutide [RDNA Origin] Injection.; (2010). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf"},{"key":"4655_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"S.P. Marso, G.H. Daniels, K. Brown-Frandsen et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016). https:\/\/doi.org\/10.1056\/nejmoa1603827","journal-title":"N. Engl. J. Med."},{"key":"4655_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"T.A. Wadden, A.M. Chao, S. Machineni et al., Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nat. Med. 29, 1\u201310 (2023). https:\/\/doi.org\/10.1038\/s41591-023-02597-w","journal-title":"Nat. Med."},{"key":"4655_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","volume":"86","author":"W Qin","year":"2024","unstructured":"W. Qin, J. Yang, Y. Ni et al., Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 86, 70\u201384 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03896-z","journal-title":"Endocrine"},{"key":"4655_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3803\/enm.2024.2164","volume":"40","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"A.B.M. Kamrul-Hasan, M.S. Alam, D. Dutta, T. Sasikanth, F.T.Z. Aalpona, L. Nagendra, Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis. Endocrinol. Metabolism. 40, 112\u2013124 (2025). https:\/\/doi.org\/10.3803\/enm.2024.2164","journal-title":"Endocrinol. Metabolism"},{"key":"4655_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2337\/diabetes.53.suppl_3.s225","volume":"53","author":"G Kwon","year":"2004","unstructured":"G. Kwon, C.A. Marshall, K.L. Pappan, M.S. Remedi, M.L. McDaniel, Signaling Elements Involved in the Metabolic Regulation of mTOR by Nutrients, Incretins, and Growth Factors in Islets. Diabetes. 53, 225\u2013S232 (2004). https:\/\/doi.org\/10.2337\/diabetes.53.suppl_3.s225","journal-title":"Diabetes"},{"key":"4655_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1210\/jc.2011-2407","volume":"97","author":"B Gier","year":"2012","unstructured":"B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, M.W. Yeh, Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland. J. Clin. Endocrinol. Metabolism. 97, 121\u2013131 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2407","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"4655_CR21","doi-asserted-by":"publisher","unstructured":"B. Waser, A. Blank, E. Karamitopoulou, A. Perren, J.C. Reubi, Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28, 391\u2013402 (2015), https:\/\/doi.org\/10.1038\/modpathol.2014.113","DOI":"10.1038\/modpathol.2014.113"},{"key":"4655_CR22","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1210\/en.2011-1864","volume":"153","author":"LW Madsen","year":"2012","unstructured":"L.W. Madsen, J.A. Knauf, C. Gotfredsen et al., GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation. Endocrinology. 153, 1538\u20131547 (2012). https:\/\/doi.org\/10.1210\/en.2011-1864","journal-title":"Endocrinology"},{"key":"4655_CR23","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1210\/jc.2010-1324","volume":"96","author":"K Timper","year":"2011","unstructured":"K. Timper, J. Grisouard, T. Radimerski et al., Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Calcitonin Gene-Related Peptide (CGRP)-I and Procalcitonin (Pro-CT) Production in Human Adipocytes. J. Clin. Endocrinol. Metabolism. 96, E297\u2013E303 (2011). https:\/\/doi.org\/10.1210\/jc.2010-1324","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"4655_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fendo.2013.00071","volume":"4","author":"H Kwon","year":"2013","unstructured":"H. Kwon, J.E. Pessin, Adipokines Mediate Inflammation and Insulin Resistance. Front. Endocrinol. 4, 71 (2013). https:\/\/doi.org\/10.3389\/fendo.2013.00071","journal-title":"Front. Endocrinol."},{"key":"4655_CR25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2337\/dbi21-0001","volume":"70","author":"M Fukuda","year":"2021","unstructured":"M. Fukuda, The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 70, 1929\u20131937 (2021). https:\/\/doi.org\/10.2337\/dbi21-0001","journal-title":"Diabetes"},{"key":"4655_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.13427","volume":"127","author":"HL Zakariassen","year":"2020","unstructured":"H.L. Zakariassen, L.M. John, T.A. Lutz, Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic Clin. Pharmacol. Toxicol. 127, 163\u2013177 (2020). https:\/\/doi.org\/10.1111\/bcpt.13427","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"4655_CR27","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1210\/endo.136.11.7588259","volume":"136","author":"JE Garrett","year":"1995","unstructured":"J.E. Garrett, H. Tamir, O. Kifor et al., Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology. 136, 5202\u20135211 (1995). https:\/\/doi.org\/10.1210\/endo.136.11.7588259","journal-title":"Endocrinology"},{"key":"4655_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3803\/enm.2021.1082","volume":"36","author":"M Kim","year":"2021","unstructured":"M. Kim, B.H. Kim, Current Guidelines for Management of Medullary Thyroid Carcinoma, Endocrinol. Metabolism. 36, 514\u2013525 (2021). https:\/\/doi.org\/10.3803\/enm.2021.1082","journal-title":"Endocrinol. Metabolism"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04655-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:17:31Z","timestamp":1777879051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04655-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4655"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04655-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines outlined in the Declaration of Helsinki. Approval was obtained from the ethical committee of the Hellenic Endocrine Network (Protocol Number: \u039d2024\/0121316). Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"180"}}